Acumen Pharmaceuticals, Inc.

NASDAQ: ABOS · Healthcare · Biotechnology

PublicHQ Newton, VACIK 0001576885Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 37DQ —GM —SS 46

v0.1 · 35/100 weight · pillars only

↑ market scale, balance-sheet leverage · ↓ listing tenure, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$121.3M

Employees

Market cap

$166.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$121.3M-$121.3M2025

Operating income-$123.8M-$123.8M2025

Total assets$122.8M$122.8M2025

Liabilities$52.4M$52.4M2025

Equity$70.4M$70.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Acumen Pharmaceuticals, Inc. earned -$121.3M in FY2025 net income.

Peers · Healthcare

Pyxis Oncology, Inc.27D Healwell AI Inc.59C Q32 Bio Inc.70B NervGen Pharma Corp. Common stock——

Key facts

CEODaniel J. O'Connell

SectorHealthcare

IndustryBiotechnology

HeadquartersNewton, VA

ExchangeNASDAQ: ABOS

Employees61

IPO date2021-07-01

Latest filings

8-K2026-06-16 8-K2026-06-03 10-Q2026-05-12 8-K2026-05-12 DEF 14A2026-04-23 8-K2026-03-26 10-K2026-03-26 8-K2026-03-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.